Navigation Links
Drug kills cancer cells by restoring faulty tumor suppressor
Date:5/14/2012

A new study describes a compound that selectively kills cancer cells by restoring the structure and function of one of the most commonly mutated proteins in human cancer, the "tumor suppressor" p53. The research, published by Cell Press in the May 15th issue of the journal Cancer Cell, uses a novel, computer based strategy to identify potential anti-cancer drugs, including one that targets the third most common p53 mutation in human cancer, p53-R175H. The number of new cancer patients harboring this mutation in the United States who would potentially benefit from this drug is estimated to be 30,000 annually.

P53 recognizes cellular stress and either puts the brakes on cell proliferation, or kills the cell if the damage is irreparable. The gene encoding p53 is mutated in over half of human cancers, and loss of p53 function has been linked to many aspects of cancer including aggressiveness, metastasis and poor response to chemotherapy and radiation. "Restoring the function of mutant p53 with a drug has long been recognized as an attractive cancer therapeutic strategy," explains senior study author, Dr. Darren R. Carpizo, from The Cancer Institute of New Jersey. "However, it has proven difficult to find compounds that restore the lost function of a defective tumor-suppressor."

Dr. Alexei Vazquez, a co-author of the study, developed a computer based screening method to identify compounds that target tumor cells with p53 mutations, but not cells with normal p53. The screening method was unique because it involved cancer cells with diverse genetic backgrounds, a model that recapitulates what is seen in actual human cancers. This method identified several compounds that killed cancer cells containing mutant p53. One of the compounds did so by restoring the structure and function of the p53-R175H mutant. The researchers went on describe the details of the reactivation mechanism and showed that normal cells were not impacted by the compound.

In addition to identifying a compound for selectively restoring the function of the p53-R175H mutant, the findings also support the development of rationally targeted cancer therapies. "Anti-cancer drug development is moving in the direction of "personalized medicine" in which the drugs are chosen based on the molecular pathways that are deranged in an individual patient's tumor," concludes Dr. Carpizo. "Our findings support the growing trend in developmental therapeutics in which the efficacy of future cancer drugs will depend upon the knowledge of the patient's tumor genotype."


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
2. More Evidence Bilingualism Aids Thinking Skills
3. Parents poor math skills may lead to medication errors
4. Physicians mindfulness skills can improve care for patient and provider
5. Study determines critical skills for PCPs to safely manage opioid risk in chronic pain patients
6. Poor Reading Skills Might Be Fatal for Older Folks
7. New compound discovered that rapidly kills liver cancer
8. Hepatitis C Now Kills More Americans Than HIV
9. Blocking telomerase kills cancer cells but provokes resistance, progression
10. Autism affects motor skills, study indicates
11. A leukemia drug kills cancerous T-cells while sparing normal immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... ... 31, 2016 , ... CURE Media Group , the ... added Cancer and Careers to its Advocacy Spotlight Partnership ... successful careers while fighting cancer. , As partners, both organizations will supply timely ...
(Date:5/30/2016)... Miami, FL (PRWEB) , ... May 30, 2016 , ... ... will means for their children and their efforts to keep their households lice free. ... schools across Hawaii are enacting new policies that keep kids in the classroom despite ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... Eye expert s ... seek an eye examination before leaving ...   Moorfields Eye Hospital Dubai, the first overseas branch ... , has identified premature babies as a special concern in the ... vulnerability to retinopathy of prematurity (ROP). ROP is a potentially blinding ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology: